Dr. Gregory Riely on Potential Treatment for Patients With MET Exon 14 Mutation
Gregory J. Riely, MD, PhD, vice chair of the Clinical Trials Office in the Department of Medicine, Memorial Sloan Kettering Cancer Center, talks about non-small cell lung cancer (NSCLC) MET exon 14 mutations and their response to drugs like cabozantinib and crizotinib.
Gregory J. Riely, MD, PhD, vice chair of the Clinical Trials Office in the Department of Medicine, Memorial Sloan Kettering Cancer Center, talks about non-small cell lung cancer (NSCLC) MET exon 14 mutations and their response to drugs like cabozantinib and crizotinib. Riely says response rate of patients with NSCLC MET exon 14 mutation to treatments like cabozantinib and crizotinib are over 50%.
Riley adds that the next step for these findings, despite only 4% of NSCLC patients having the MET exon 14 mutation, is to translate them into prospective trials. He says the first of the trials will deal with crizotinib.
